Wanbury Limited , a prominent pharmaceutical company, has announced strong financial results for the second quarter and first half of fiscal year 2026, showcasing significant growth across key metrics.

Financial Highlights

The company reported impressive gains for H1FY26:

Q2FY26 Performance

For the second quarter of FY26, Wanbury reported:

• Revenue from Operations: 160.10 crore
• EBITDA: 26.00 crore, up 20.10% YoY
• EBITDA Margin: 16.20%, an improvement of 292 bps YoY
• PAT: 15.20 crore, showing a significant growth of 89.30% YoY
• PAT Margin: 9.50%, up from 4.90% in Q2FY25

Key Growth Drivers

The company's robust performance can be attributed to several factors:

1. Volume Growth: Increased sales volumes contributed to the revenue uptick.
2. Cost Efficiencies: Improved operational efficiency and cost management.
3. Product Yield Enhancement: Better production yields boosted profitability.
4. Lower Finance Costs: Reduced financial expenses positively impacted the bottom line.
5. Procurement Efficiencies: Optimized sourcing for raw materials and supplies.
6. Field Force Productivity: Enhanced sales team performance and promotional activities.

Strategic Initiatives

Wanbury has implemented several strategic initiatives to drive growth:

1. Digital Transformation: The company has implemented SAP S/4HANA Private Cloud, enhancing operational agility and data-driven decision-making.
2. New Product Introduction: Successfully launched a liposomal iron supplement.
3. Brand Promotion: Increased focus on various brand promotional activities.
4. Training Programs: Targeted training to improve sales force productivity.

Management Commentary

Mr. K S Rayana, Director of Wanbury Ltd., commented on the results: "Q2 continued our robust growth trajectory, with PAT of 15.20 crore in Q2 FY26, a 89.30% increase compared to 8.00 crore in Q2 FY25. This improvement was driven by cost efficiencies, improved product yield, and lower finance costs."

He further added, "Our efforts are aimed at strengthening Wanbury's position as a trusted global pharmaceutical partner while driving long-term value for all stakeholders."

Future Outlook

Wanbury remains focused on:

1. Sustaining operational efficiencies
2. Expanding production capacities
3. Maintaining high-quality standards
4. Introducing new products
5. Strengthening its position in the global pharmaceutical market

The company's strong H1FY26 performance, coupled with its strategic initiatives, positions Wanbury for continued growth in the pharmaceutical sector.

Note: All financial figures are in Indian Rupees (₹) crore.

Wanbury Limited , a prominent player in the pharmaceutical sector, has announced its financial results for the second quarter of FY26, showcasing a robust performance and strategic corporate actions.

Financial Highlights

Wanbury reported significant growth in its quarterly results:

The company achieved an EBITDA of ₹26.00 crore (16.20% margin) in Q2 FY26 compared to ₹21.60 crore (13.30% margin) in Q2 FY25, marking 20% growth. This performance indicates a strong financial position and operational efficiency, driven by enhanced product yields and procurement efficiencies.

Wanbury's PAT surged 89% to ₹15.20 crore from ₹8.00 crore year-over-year, demonstrating significant bottom-line improvement.

Business Segment Performance

• The formulations business turned EBITDA positive
• The API business maintained strong performance

Strategic Initiatives

The company highlighted successful digital transformation efforts and expressed commitment to sustainable growth through new product launches. Notably, Wanbury successfully launched a new iron supplement brand called C-red.

Employee Stock Option Plan

Wanbury's Board approved the allotment of 15,000 equity shares under its Employee Stock Option Plan 2016 (WANBURY ESOP 2016). These shares, with a face value of ₹10 each, were issued at par to an eligible employee who exercised vested options.

Impact on Share Capital

Following this allotment, Wanbury's paid-up share capital has increased to ₹34,89,19,980, divided into 3,48,91,998 fully paid-up equity shares of ₹10 each. This represents an increase from the previous share capital of ₹34,87,69,980.

Corporate Actions

During the quarter, the company also allotted 20,00,000 equity shares upon the exercise of conversion options attached to warrants. This resulted in an increase of ₹200.00 lakhs in the paid-up share capital and ₹2,200.00 lakhs in the Securities Premium account.

Management Commentary

The management expressed satisfaction with the company's performance, highlighting the success of their business model and the dedication of their team. The allotment of employee stock options underscores their commitment to aligning the workforce with the company's long-term success.

Future Outlook

Wanbury continues to focus on its core pharmaceutical segment, leveraging its US FDA-approved manufacturing facilities in Tanuku (Andhra Pradesh) and Patalganga (Maharashtra) to drive growth. The company's commitment to sustainable growth through new product launches, as evidenced by the introduction of C-red, suggests a positive outlook for future quarters.